wildfires.jpg
Our hearts go out to those affected by the recent LA wildfires. To support relief efforts, we are donating a portion of our sales to local charities working to rebuild the community.

FDA Regulation of Artificial Intelligence/ Machine Learning

Edwin Waldbusser
Duration: 60 Minutes
Webinar Id: 23542
Instructor: Edwin Waldbusser

Price Details

Recorded Webinar
$190. One Attendee
$390. Unlimited Attendees

Unlimited Attendees: Any number of participants

Recorded Version: Unlimited viewing for 6 months (Access information will be emailed 24 hours after the completion of live webinar)

Overview:

AI/ ML will revolutionize medicine by making diagnosis and treatment more accessible and more effective.

FDA has regulated medical device software by means of regulation and guidance’s for years, however, AI/ML programs fall outside the scope of these regulations and guidance’s. This happens because FDA approves the final, validated version of the software. The objective of AI/ML is to learn and update following deployment using real world data to improve performance. Thus the deployed version of the software is no longer the validated approved version. Also, according to current regulation, significant changes require a new 510(k) submission. The objective of AI/ML is to create significant change post release. A new submission for each update would be impractical.

FDA, in January 2025, released a draft Guidance explaining the documentation required to obtain clearance/ approval for a ML product. This training will explain ML terminology and the ML development process, address the inadequacy of the current regulations, and explain in detail the procedures described in the draft Guidance. The new approach, a Predetermined Change Control Program (PCCP) will be explained.

This webinar is not a programming course but will explain the present and future regulatory requirements for AI/ML. Attendees will receive a multipage outline and checklist.

Why you should Attend:

It has not been clear how to get AI/ML programs approved. The regulatory requirements, up to now, don’t control AI/ML adequately. 

We will discuss the approaches FDA will take for regulation as described in the  2025 draft Guidance. Necessary submission documentation will be explained including the new approach of a PCCP.

Areas Covered in the Session:

  • FDA Discussion Paper on device AI/ML and Action Plan
  • Database management
  • QC of datasets
  • Preliminary Change Control Plan (PCCP)
  • Reference standard development
  • Standalone performance testing
  • Clinical performance testing
  • Emphasis on "explainability"
  • Cybersecurity

Who Will Benefit:

  • Software Engineers
  • Engineers
  • Regulatory Personnel
  • Quality Assurance Personnel
  • Marketing
  • Management

Speaker Profile
Edwin Waldbusser is a consultant retired from industry after 20 years in management of development of medical devices (5 patents). He has been consulting in the US and internationally in the areas of design control, risk analysis and software validation for the past 8 years. Mr. Waldbusser has a BS in Mechanical Engineering and an MBA. He is a Lloyds of London certified ISO 9000 Lead Auditor and a member of the Thomson Reuters Expert Witness network.

Sign Up for Our Newsletter